Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

TYRA - Tyra Biosciences, Inc.


IEX Last Trade
14.08
-0.040   -0.284%

Share volume: 2,533
Last Updated: Fri 27 Dec 2024 08:30:17 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%

$14.12
-0.04
-0.28%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
3.16%
1 Month
-8.13%
3 Months
-37.02%
6 Months
-4.85%
1 Year
5.00%
2 Year
71.53%
Key data
Stock price
$14.08
P/E Ratio 
0.00
DAY RANGE
$14.11 - $14.58
EPS 
$0.00
52 WEEK RANGE
$12.06 - $29.60
52 WEEK CHANGE
$6.14
MARKET CAP 
1.202 B
YIELD 
N/A
SHARES OUTSTANDING 
52.806 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
1.73
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$254,225
AVERAGE 30 VOLUME 
$219,599
Company detail
CEO: Todd J. Harris
Region: US
Website: tyra.bio
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Tyra Biosciences, Inc. focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.

Recent news